Debra Yu - 31 Oct 2021 Form 4 Insider Report for LianBio (LIAN)

Role
President & Chief Strategy Officer
Signature
By: /s/ Angela Chen, Attorney-in-Fact
Issuer symbol
LIAN
Transactions as of
31 Oct 2021
Transactions value $
$0
Form type
4
Filing time
01 Nov 2021, 19:19:01 UTC
Previous filing
29 Oct 2021
Next filing
27 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIAN Stock Option (Right to Buy) Award $0 +747K +37.36% $0.00 2.75M 31 Oct 2021 Ordinary Shares 747K $16.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the shares underlying the option will vest and become exercisable on October 31, 2022; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on October 31, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.

Remarks:

President & Chief Strategy Officer